Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
66,505,186
-
Number of holders
-
22
-
Total 13F shares, excl. options
-
4,622,322
-
Shares change
-
+4,622,322
-
Total reported value, excl. options
-
$9,565,000
-
Value change
-
+$9,565,000
-
Number of buys
-
22
-
Price
-
$2.06
Significant Holders of Regulus Therapeutics Inc. - Common Stock, par value $0.001 per share - Put (RGLS) as of Q2 2022
23 filings reported holding RGLS - Regulus Therapeutics Inc. - Common Stock, par value $0.001 per share - Put as of Q2 2022.
Regulus Therapeutics Inc. - Common Stock, par value $0.001 per share - Put (RGLS) has 22 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 4,622,322 shares
of 66,505,186 outstanding shares and own 7% of the company stock.
Largest 10 shareholders include FEDERATED HERMES, INC. (2,904,826 shares), DAFNA Capital Management LLC (555,555 shares), VANGUARD GROUP INC (372,732 shares), VICTORY CAPITAL MANAGEMENT INC (221,506 shares), Sarissa Capital Management LP (185,183 shares), Ikarian Capital, LLC (105,341 shares), GEODE CAPITAL MANAGEMENT, LLC (71,857 shares), STATE STREET CORP (41,719 shares), RENAISSANCE TECHNOLOGIES LLC (28,100 shares), and CITADEL ADVISORS LLC (23,655 shares).
This table shows the top 22 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.